NCT07059546View on ClinicalTrials.gov

Hypersensitivity to Adrenomedullin in Post-Traumatic Headache

NARecruitingINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

August 1, 2025

Primary Completion Date

May 1, 2028

Study Completion Date

December 1, 2028

Conditions
Posttraumatic Headache
Interventions
DRUG

Adrenomedullin

The participants will receive continuous intravenous infusion of 20 mL of 19.9 pmol/kg/min adrenomedullin over 20 minutes.

DRUG

Placebo

The participants will receive a continuous intravenous infusion of 20 mL of placebo (isotonic saline) over 20 minutes.

Trial Locations (1)

2600

RECRUITING

Rigshospitalet-Glostrup, Glostrup Municipality

All Listed Sponsors
lead

Danish Headache Center

OTHER

NCT07059546 - Hypersensitivity to Adrenomedullin in Post-Traumatic Headache | Biotech Hunter | Biotech Hunter